RNA interference (RNAi) may be used as a therapeutic for the bleeding disorder hemophilia. Specifically, artificially-generated, epigenetically-activated RNA molecules such as microRNAs can be used to inhibit gene expression through post-translational gene silencing. Researchers from France and the USA recently treated hemophiliac mice and macaques with a successful RNAi compound (ALN-AT3), which supresses the production of the anti-clotting substance antithrombin. Currently this therapeutic is being investigated in phase 1 clinical trials in individuals with hemophilia A or B.
To ensure you see the information most relevant to you, please select your country.
Please note that your browser will need to be configured to accept cookies.
Diagenode will process your personal data in strict accordance with its privacy policy. This will include sending you updates about us, our products, and resources we think would be of interest to you.